MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Non-Hodgkin's Lymphoma Clinical Trial

Official title:

A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00430352
• Other study ID #: MO19872
• Status: Completed
• Phase: Phase 4
• First received: January 31, 2007
• Last updated: June 3, 2015
• Start date: September 2006
• Est. completion date: May 2011

Study information

• Verified date: June 2015
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma. All patients will receive MabThera 375mg/m2 body surface area, as an intravenous infusion, every 8 weeks. The anticipated time on study treatment is 1-2 years, and the target sample size is 500+ individuals.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 545
• Est. completion date: May 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• adult patients, >=18 years of age;

• histologically confirmed grade 1, 2 or 3a follicular non-Hodgkin's lymphoma;

• patients who have received adequate (>=8 cycles) induction therapy with MabThera as first line treatment, or treatment for relapsed disease;

• demonstrated partial or complete response to induction therapy.

Exclusion Criteria:

• stable or progressive disease after most recent induction therapy;

• transformation to high grade lymphoma;

• patients with prior or concomitant malignancies, except non-melanoma skin cancer or adequately treated in situ cancer of the cervix.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Follicular
• Lymphoma, Non-Hodgkin
• Non-Hodgkin's Lymphoma

Intervention

Drug:
• rituximab [MabThera/Rituxan]
375mg/m2 iv every 8 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

Albania,  Argentina,  Australia,  Bosnia and Herzegovina,  Brazil,  Bulgaria,  Colombia,  Croatia,  Ecuador,  Egypt,  Finland,  Germany,  Greece,  Israel,  Italy,  Mexico,  Romania,  Russian Federation,  Slovakia,  Slovenia,  Spain,  Sweden,  Switzerland,  Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With an Adverse Event (AE) - Overall Summary	Data presented include percentage of participants with any AE, any infusion-related AE, any serious adverse event (SAE), any infusion-related SAE (counted separately from SAEs), death, and participants with toxicity as the primary cause for treatment discontinuation.	24 months	No
Secondary	Progression-Free Survival - Percentage of Participants With an Event	PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.	Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose	No
Secondary	Progression-Free Survival - Time to Event	PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.	Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose	No
Secondary	Event-Free Survival (EFS) - Percentage of Participants With an Event	The percentage of participants who experienced PD or death or required a next or new lymphoma treatment over a study period of 2 years with 1 year of follow-up. EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.	Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose	No
Secondary	Event-Free Survival (EFS) - Time to Event	EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.	Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose	No
Secondary	Overall Survival (OS) - Percentage of Participants With an Event	As a measure of overall survival (OS), the percentage of participants who died over the study period of 2 years with 1 year of follow-up. OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.	Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose	No
Secondary	Overall Survival (OS) - Time to Event	OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.	Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose	No
Secondary	Time to Next Lymphoma Treatment (NLT) - Percentage of Participants With an Event	As a measure of time to NLT (TNLT), the percentage of participants with new lymphoma treatment over a study period of 2 years with 1 year of follow-up. TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.	Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose	No
Secondary	Time to NLT - Time to Event	TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.	Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose	No
Secondary	Percentage of Participants With Response by Best Response to Study Treatment	Percentage of participants with complete response (CR), unconfirmed CR (CRu), no change, or progressive disease (PD). For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Where possible, assessment of response was based on the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma (NHL).	Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose	No
Secondary	Percentage of Participants With PR Who Converted to CRu	Percentage of participants with PR or CR(u) conversion while on rituximab maintenance therapy over a study period of 2 years with 1 year of follow-up. For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Assessment and definition of response was based on the International Workshop to Standardize Response Criteria for NHL.	Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose	No